Hyperkalemia – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Hyperkalemia is a potentially life-threatening condition in which serum potassium concentration exceeds 5.5 mEq/L. Despite various guidelines, no accepted consensus exists for the management of hyperkalemia. The aggressiveness of therapy is dependent on the rapidity with which hyperkalemia develops and absolute K+ concentration. Clinicians manage this condition in two ways: increasing K+ cell uptake (IV insulin / glucose, inhaled salbutamol) and/or increasing potassium excretion (K+ binders, diuretics). In this report, we look at the key therapies and how they are being used in the treatment of newly diagnosed and recently treated hyperkalemia patients. This report also dives into the compliance and persistency rates of drug-treated patients at the product level.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hyperkalemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hyperkalemia patients?
- How have K+ binders (Lokelma, and Veltassa) been integrated into the treatment algorithm, and what is its source of business?
- What percentage of hyperkalemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of hyperkalemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AstraZeneca, Vifor Pharma
Key drugs: Lokelma, Veltassa
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
- Hyperkalemia - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Hyperkalemia US July 2023
- Treatment Algorithms CDA Hyperkalemia 2023 Dashboard
Carles Recasens-Alvarez, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematology. Prior to joining Clarivate, Dr. Recasens-Alvarez was a postdoctoral researcher in the laboratory of Jean-Paul Vincent at the Francis Crick Institute (London), where he investigated the role of protein misfolding and cellular stress in the etiology of ribosomopathies and lead-authored a manuscript. For his doctoral research, he studied the role of cell cycle and apoptosis in development in the laboratory of Professor Marco Milan at the Institute for Research in Biomedicine (Barcelona). He holds a Ph.D. and an M.Sc. in genetics, both from the University of Barcelona, and a B.Sc. in biology from the Autonomous University of Barcelona.
Karan Madhok, B.D.S., is an associate analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. Prior to joining this company, he worked in the intelligence and insight division of Prescient Healthcare Group. He has experience in various therapeutic domains, including rheumatology, immunology, oncology, and rare diseases, and has been extensively involved in client and project management. He holds a B.D.S. degree from Manipal College of Dental Sciences in Manipal, India.